Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma

[1] Kumar SK(2017)Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study Leukemia 31 2443-8

[2] Dimopoulos MA(2019)Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy Leukemia 33 2266-75

[3] Kastritis E(2013)B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma Clin Cancer Res 19 2048-60

[4] Terpos E(2004)Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival Blood 103 689-94

[5] Nahi H(2007)Regulated expression of BAFF-binding receptors during human B cell differentiation J Immunol 179 7276-86

[6] Goldschmidt H(2011)Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1 Blood 117 4691-5

[7] Gandhi UH(2019)Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study Blood Cancer J 9 121-35

[8] Cornell RF(2018)Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads Investig New Drugs 36 1641-53

[9] Lakshman A(2018)Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial Lancet Oncol 19 207-21

[10] Gahvari ZJ(2020)Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study Lancet Oncol 21 undefined-undefined

[1] Kumar SK(2017)Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study Leukemia 31 2443-8

[2] Dimopoulos MA(2019)Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy Leukemia 33 2266-75

[3] Kastritis E(2013)B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma Clin Cancer Res 19 2048-60

[4] Terpos E(2004)Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival Blood 103 689-94

[5] Nahi H(2007)Regulated expression of BAFF-binding receptors during human B cell differentiation J Immunol 179 7276-86

[6] Goldschmidt H(2011)Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1 Blood 117 4691-5

[7] Gandhi UH(2019)Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study Blood Cancer J 9 121-35

[8] Cornell RF(2018)Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads Investig New Drugs 36 1641-53

[9] Lakshman A(2018)Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial Lancet Oncol 19 207-21

[10] Gahvari ZJ(2020)Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study Lancet Oncol 21 undefined-undefined